Virus-mediated suppression of the antigen presentation Molecule MR1 by McSharry, Brian P. et al.
ArticleVirus-Mediated Suppression of the Antigen
Presentation Molecule MR1Graphical AbstractHighlightsd The herpesviruses HSV-1 and CMV suppress the antigen
presentation molecule MR1
d HSV-1 targets immature MR1 for degradation although
mature MR1 remains protected
d The Us3 protein of HSV-1 is partially responsible for
suppression of MR1
d Suppression of MR1 by HSV-1 inhibits MAIT TCR-dependent
activationMcSharry et al., 2020, Cell Reports 30, 2948–2962
March 3, 2020 ª 2020 The Authors.
https://doi.org/10.1016/j.celrep.2020.02.017Authors
Brian P. McSharry, Carolyn Samer,
Hamish E.G. McWilliam, ...,
Jose A. Villadangos, Jamie Rossjohn,
Barry Slobedman
Correspondence
barry.slobedman@sydney.edu.au
In Brief
The antigen-presenting molecule MR1
presents bacterial and fungal metabolites
to MAIT cells. McSharry et al. show that
the herpesviruses HSV-1 and CMV
disrupt MR1 expression. Downregulation
of MR1 by HSV-1 inhibits bacterially
driven MAIT TCR-dependent activation.
This provides evidence of virus
immunomodulatory control of the MR1-
restricted immune response.
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https://doi.org/10.1016/j.celrep.2020.02.017SUMMARY
The antigen-presenting molecule MR1 presents
microbial metabolites related to vitamin B2 biosyn-
thesis to mucosal-associated invariant T cells (MAIT
cells). Although bacteria and fungi drive the MR1
biosynthesis pathway, viruses have not previously
been implicated in MR1 expression or its antigen pre-
sentation. We demonstrate that several herpesvi-
ruses inhibit MR1 cell surface upregulation, including
a potent inhibition by herpes simplex virus type 1
(HSV-1). This virus profoundly suppresses MR1 cell
surface expression and targets the molecule for pro-
teasomal degradation, whereas ligand-induced cell
surface expression of MR1 prior to infection enables
MR1 to escape HSV-1-dependent targeting. HSV-1
downregulation of MR1 is dependent on de novo viral
gene expression, and we identify the Us3 viral gene
product as functioning to target MR1. Furthermore,
HSV-1 downregulation ofMR1disruptsMAIT T cell re-
ceptor (TCR) activation. Accordingly, virus-mediated
targeting ofMR1defines an immunomodulatory strat-
egy that functionally disrupts the MR1-MAIT TCR
axis.
INTRODUCTION
Themajor histocompatibility complex (MHC) class I-related gene
protein (MR1) is an antigen (Ag) presentation molecule first iden-2948 Cell Reports 30, 2948–2962, March 3, 2020 ª 2020 The Author
This is an open access article under the CC BY-NC-ND license (http://tified through sequence homology with classical human leuko-
cyte antigen (HLA) molecules (Hashimoto et al., 1995). Like
MHC I molecules, the extracellular domain of the MR1 heavy
chain has a1, a2, and a3 domains. Unlike MHC I, however,
MR1 is monomorphic and is highly conserved across mamma-
lian species (Yamaguchi et al., 1997). A potential biological func-
tion for MR1 was initially identified in MR1/ mice, which lack a
subset of T cells known as mucosal associated invariant T cells
(MAIT cells) (Treiner et al., 2003). This and subsequent studies
have defined MR1 as a restriction element for MAIT cells (Kjer-
Nielsen et al., 2012; Treiner et al., 2003).
MAIT cells are primarily a population of ab T cells, highly abun-
dant in humans, and typically express an invariant T cell receptor
(TCR) a chain (TRAV1-2-TRAJ33; Fernandez et al., 2015; Gherar-
din et al., 2016). MAIT cells are characterized as innate-like cells
that have the ability to rapidly respond to a range of bacterial and
fungal pathogens (Gold et al., 2010; Howson et al., 2015; Le
Bourhis et al., 2013). The mechanism by which MAIT cells can
recognize these infectionswas shown to be via pathogenmetab-
olites derived from a biosynthetic precursor to vitamin B2 (Vit
B2), which bind to MR1 to induce trafficking to the cell surface
and subsequent TCR-mediated MAIT cell activation (Corbett
et al., 2014; Eckle et al., 2014; Kjer-Nielsen et al., 2012; Patel
et al., 2013). More recently, it has also been reported that MR1
has the capacity to bind and present a broader repertoire of li-
gands from both bacterial and non-bacterial sources (Harriff
et al., 2018; Keller et al., 2017).
This identification of MR1-bound metabolites has facilitated a
characterization of the MR1 processing and presentation
pathway. Unlike other antigen presentation molecules, such as
MHC I and CD1, that constitutively bind host peptides or lipids,s.
creativecommons.org/licenses/by-nc-nd/4.0/).
respectively, MR1 primarily resides in an immature state in the
endoplasmic reticulum (ER) (McWilliam et al., 2016). Ligand
binding to MR1 in the ER triggers a ‘‘molecular switch’’ that
drives MR1 to fully mature, associate with b2-microglobulin,
and traffic to the cell surface, where it can activate MAIT cells
(McWilliam et al., 2016).
Human herpesvirus infections are associated with several sig-
nificant morbidities. Herpes simplex virus type 1 (HSV-1) is a
ubiquitous alpha herpesvirus associated with recurrent orofacial
and other infections and remains the most common cause of
viral encephalitis (Tyler, 2018). As with all herpesviruses, primary
infection is followed by lifelong persistence. It is well established
that persistence of herpesvirus infections is facilitated by viral
encoded proteins that mediate a multitude of strategies to regu-
late the host immune response. Definition and elucidation of viral
mechanisms of immune control have led to fundamental insights
into pathways key to immune effector functions (van de Weijer
et al., 2015). Such immunomodulatory activities include the abil-
ity of HSV-1 to limit Ag presentation through both MHC I and
CD1d to control both classical T cell and NKT cell responses,
respectively (Fr€uh et al., 1995; Rao et al., 2011; York et al.,
1994; Yuan et al., 2006).
Recently, it has become clear that viral infection can modulate
both circulating MAIT cell number and function (Barathan et al.,
2016; Cosgrove et al., 2013; Eberhard et al., 2014; Fernandez
et al., 2015; Hengst et al., 2016; Hofmann and Thimme, 2016; Pa-
quin-Proulx et al., 2017; Vinton et al., 2016), and MAIT cells can
be activated by viral infection; however, this is driven in an MR1-
independent fashion by cytokines, including interleukin-12
(IL-12) and IL-18 (Loh et al., 2016; Paquin-Proulx et al., 2018;
van Wilgenburg et al., 2016). There have been no reports of a
link between viral infection and modulation of MR1. In this study,
we have identified multiple herpesviruses that inhibit surface
expression of MR1. We focus on that encoded by HSV-1 and
identify a viral-encoded immunoevasin that limits MR1 surface
expression. This study reports a viral immunomodulatory activity
through a pathway previously unidentified as a target of viral
infection.
RESULTS
Surface and Cellular MR1 Are Profoundly
Downregulated during Herpesvirus Infections
Given the well-defined capacity of a number of viral infections to
regulate expression of MHC I and MHC-I-like molecules, the
ability of several viruses to modulate MR1 surface expression
was tested. Initially, we focused on MR1 regulation during viral
infection of fibroblasts. As expected, cell surface expression of
MR1 in human fibroblasts (HFFs) in the absence of exogenous
ligand was minimal; however, upon addition of the synthetic
MR1 ligand, Ac-6-FP, surface MR1 was readily detectable (Fig-
ure S1). Infection with the herpesviruses HSV-1, human cyto-
megalovirus (HCMV), and murine cytomegalovirus (MCMV) prior
to ligand addition resulted in a potent inhibition of MR1 surface
upregulation in both human and murine fibroblasts, respectively
(Figure 1A). In contrast, the DNA virus, adenovirus (Ad) serotype
5, which is well known for its ability to target both MHC and
MHC-like molecules (Burgert and Kvist, 1985; Burgert et al.,1987; McSharry et al., 2008), was incapable of inhibiting MR1
surface expression during infection of HFFs (Figure 1A). To
extend this initial observation, we confirmed that Ad infection
also did not modulate MR1 surface expression in 293 cells, a
line in which it has been shown that the Ad-encoded glycopro-
tein E3/19K can downregulate surface HLA (Figure S2). These
data indicate that the ability of HSV-1, HCMV, andMCMV to sup-
press MR1 was not an inherent response to DNA virus infection.
To define the mechanism by which MR1 was targeted during
virus infection, we focused on HSV-1. We overexpressed MR1
in an epithelial cell line (ARPE-19) to facilitate western blot anal-
ysis of MR1 levels post-infection (p.i.), and co-expressed EGFP
from the same promoter via a downstream internal ribosomal
entry site (IRES) (McWilliam et al., 2016). A time course analysis
(0, 2, 4, and 6 h p.i.) of MR1 protein levels by western blotting in
HSV-1-infected cells indicated that MR1 protein was reduced at
very early timeswith a profound loss inMR1 levels obvious by 6 h
p.i. and MR1 at near undetectable levels by 18 h p.i. (Figure 1B).
At 6 h p.i., there was a significant but limited downregulation
(2-fold) of surface levels of MR1 (Figure S3), which by 18 h p.i.
showed an almost 10-fold reduction in surface MR1 (Figure 1C),
mirroring the loss of total MR1 protein. As previously established
(Fr€uh et al., 1995; York et al., 1994), surface MHC I expression
was also significantly downregulated by viral infection (Fig-
ure 1C). It is important to note that GFP levels, driven from the
same expression cassette, were unchanged by HSV-1 infection,
as measured by western blotting and flow cytometry at all times
assayed (Figures 1B and 1C), suggesting specific targeting of
MR1 by HSV-1. Together, this implies that HSV-1 infection can
target the MR1 protein to limit surface expression.
Ligand-Induced Surface MR1 Is Protected from HSV-1-
Mediated Loss
Current evidence indicates that the functional role for MR1 de-
tected to date is dependent on its ability to present antigen
(Kjer-Nielsen et al., 2012). Therefore, we addressed how addition
of MR1 ligand affects HSV-1 targeting of MR1. ARPE-19 MR1
cells were either treated pre-infection with the MR1 ligand, Ac-
6-FP, or treated at 14 h p.i. before MR1 surface expression
was then measured at 18 h p.i. When cells were treated with
Ac-6-FP p.i. again there was a potent loss of MR1 surface stain-
ing (>40-fold) compared to mock infected cells (Figure 2).
Remarkably, when cells were treated with ligand prior to infec-
tion, there was no longer a virus-induced suppression of surface
MR1 expression, and we even noticed a small but statistically
significant increase in MR1 surface expression levels in HSV-1
compared to mock infected cells (Figure 2A). In contrast, MHC
I surface expression was strongly inhibited under both condi-
tions (Figure 2), suggesting a fundamental difference in the
way in which HSV-1 targets MR1 and MHC I, respectively.
To investigate the mechanism underpinning this regulation of
MR1, lysates prepared from mock and HSV-1-infected cells
that had been treated with Ac-6-FP pre-infection or p.i. were di-
gested with endoglycosidase H (EndoH) before western blotting
as a means to differentiate between the immature MR1 mole-
cules that remain in the ER or the mature MR1 that have been
processed through the ER/Golgi apparatus, before western
blotting (Figure 2C). As demonstrated previously, Ac-6-FPCell Reports 30, 2948–2962, March 3, 2020 2949
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Figure 1. Viral Infection Inhibits MR1 Protein Expression
(A) HFFs (HCMV, HSV-1, and Ad) or NIH 3T3 fibroblasts (MCMV) were infected with the indicated viruses. Cells were treated with Ac-6-FP p.i. for 16 h before
staining for surface MR1 at the following times p.i. HSV-1 (24 h), HCMV (24 h), Ad (24 h), or MCMV (18 h). Isotype (gray), mock (blue), and virus (red) staining are
indicated. Data are representative of at least 3 independent experiments.
(B) Cell lysates from mock or HSV-1-infected ARPE-19 MR1 cells were harvested at 0, 2, 4, 6, and 18 h p.i. before immunoblotting for MR1, GFP, and GAPDH.
Data are representative of at least 2 independent experiments.
(C)ARPE-19MR1weremockorHSV-1 infectedbeforestaining for surfaceMR1,MHCI,or isotypecontrol (gray) at18hp.i. andanalysisbyflowcytometry.Foldchange
relative to mock infected cells is graphed. Statistical significance was calculated by paired Student’s t test; ***p < 0.0005; ****p < 0.0001 (n = 4).
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addition induces the maturation of MR1 (McWilliam et al., 2016)
with an EndoH-resistant species detectable in mock infected
cells treated with ligand both pre-infection and p.i. In either the
cells left untreated or with ligand added p.i., there was an almost
complete loss of MR1 protein at 18 h p.i. However, in the cells
pre-treated with MR1 ligand, there was a mature EndoH-resis-
tant form of MR1 that was maintained during viral infection,
which mirrored the surface MR1 expression observed by flow
cytometry. Thus, ligand-bound, mature, surface MR1 appears
resistant to HSV-1-dependent MR1 targeting.
This differential targeting of surface MR1, which was depen-
dent on the timing of ligand addition, was also detected in
HFFs engineered to overexpress MR1 (Figure S4). Similarly,
pre-treatment with Ac-6-FP in parental HFFs protected the
endogenously expressed molecule from HSV-1-dependent tar-
geting although MR1 surface expression induced by Ac-6-FP
added p.i. was efficiently inhibited by viral infection (Figures 3A
and 3B). Interestingly, HCMV infection was capable of potently
inhibiting MR1 surface expression whether treated with ligand
pre-infection or p.i. in HFFs (Figures 3C and 3D), suggesting
distinct herpesviruses do not target MR1 via directly equivalent
mechanisms.
To further investigate HSV-1-dependent targeting of MR1,
ARPE-19 cells expressing a C-terminally tagged fusion protein,
MR1-GFP, were generated. MR1-GFP-expressing cells demon-
strated the same pattern of MR1 surface regulation post-viral
expression as untagged MR1, with the timing of ligand addition
determining whether surface MR1 expression was protected or
inhibited during infection (Figure S5A). In this experimental
setup, MR1-GFP fluorescence provided a direct readout for
levels of MR1 fusion protein expression that differed from the sit-
uation in ARPE-19 MR1 cells, where GFP is expressed via a
downstream IRES. MR1-GFP fluorescence levels were found
to be reduced in cells treated both pre- and p.i. with Ac-6-FP,
and the reduction in MR1-GFP levels was significantly more pro-
nounced when ligand was added p.i. (Figure S5B). This result is
consistent with pre-existing, cell-surface-resident, ligand-bound
MR1 molecules being resistant to HSV-1-mediated targeting.
This was alsomirrored by immunoblotting (Figure S5C), in agree-
ment with our observations with untagged MR1.
HSV-1-Mediated Loss of Surface MR1 Inhibits MR1-
Mediated Jurkat MAIT Cell Activation
To determine whether the observed viral-dependent targeting of
MR1 levels could control MR1-mediatedMAIT cell activation, we
assayed the ability of viral infection to regulate activation through
aMAIT cell TCR. Although Ac-6-FP is an efficient inducer of MR1
surface expression, it does not act as an agonist for MAIT cells.
Therefore, we first confirmed that HSV-1 infection was also
capable of efficiently inhibiting surface expression driven byFigure 2. Ligand Binding Blocks HSV-1-Dependent Targeting of MR1
(A and B) ARPE-19 MR1 cells were mock or HSV-1 infected in parallel. Cells were
p.i. (post) before staining for surface MR1, MHC I at 18 h p.i., and analysis by flow
significance was calculated by paired Student’s t test; **p < 0.005; ***p < 0.0005
(C) ARPE-19 MR1 cells were mock or HSV-1 infected in parallel. Cells were either
left untreated as indicated. Cell lysates harvested at 18 h p.i. were left undigested o
representative of two independent experiments. Endo-H-resistant MR1 is denote
2952 Cell Reports 30, 2948–2962, March 3, 2020the MAIT cell agonist 5-OP-RU (Figure S6A). Ac-6-FP and 5-
OP-RU are, for MR1, functionally very similar: they bind to
MR1 via a Schiff base (Corbett et al., 2014; Eckle et al., 2014)
and upregulate cell surface MR1 to similar levels over the first
~6 h of treatment (Eckle et al., 2014; McWilliam et al., 2016;
Mak et al., 2017). However, due to its enhanced stability and
relative cost, Ac-6-FP was primarily used for molecular analysis
of MR1 regulation during infection with 5-OP-RU used for MAIT
functional assays.
Jurkat cells engineered to express a canonical MAIT-cell-spe-
cific TCR (Jurkat MAIT) (Reantragoon et al., 2012) were then
used to assay MR1 restricted recognition. HFFs were mock or
HSV-1 infected before 5-OP-RU (10 mM) or fixed E. coli were
added at 14 h p.i. and then, 4 h later, ligand or bacteria were
washed from the system and the target cells fixed as described
previously (McWilliam et al., 2016). Jurkat MAIT cells were then
added to target cells, allowed to incubate overnight before the
levels of CD69 expression, as a marker of activation, were
measured by flow cytometry. HSV-1 infection alone did not acti-
vate Jurkat MAIT cells above mock cells (Figure 4A). Both 5-OP-
RU and E. coli-treated HFFs were capable of activating through
theMAITTCR, and this activationwasblockedwith anti-MR1anti-
body (Ab) (Figure S6B). Importantly, Jurkat MAIT cells co-incu-
bated with HSV-1-infected cells treated with E. coli or 5-OP-RU
had levels of activation that were significantly less than matched
mock infected cells, demonstrating the functional consequence
of viral control of MR1 surface expression (Figures 4B and 4C).
It is known that T cell activation can be inhibited by co-culture
with HSV-1-infected cells (Sloan et al., 2003). Thus, we
confirmed that Jurkat MAIT cells co-cultured with HSV-1-in-
fected cells were still capable of responding via TCR signaling
and were not non-specifically inhibited. 5-OP-RU added directly
to the HFFs (mock or HSV-1 infected) and Jurkat MAIT cell co-
culture could upregulate CD69 to similar levels (Figure 4D).
This is due to the fact that Jurkat MAIT cells are capable of
self-presenting antigen through MR1, i.e., 5-OP-RU added
directly to Jurkat MAIT cells efficiently upregulates CD69 expres-
sion (Figure S6C). HSV-1 infection was also capable of inhibiting
both 5-OP-RU and E. coli-induced activation driven by cells
overexpressing MR1 (ARPE-19 MR1), where bacterial-induced
activation was more pronounced (Figures 4E and 4F).
Proteasomal Inhibition Rescues HSV-1-Mediated Loss
of Cellular MR1
As the loss of MR1 protein post-HSV-1 infection is consistent
with targeting of this molecule for degradation, we assayed the
ability of proteasomal inhibition to recover MR1 levels during
infection. Mock or HSV-1-infected ARPE-19 MR1 (Figure 5A)
or ARPE-19 MR1-GFP cells (Figure 5B) were treated with the
proteasomal inhibitor MG132 immediately post viral adsorptioneither treated with Ac-6-FP (5 mM; A) for 24 h prior to infection (pre) or (B) at 14 h
cytometry. Fold change relative to mock infected cells is graphed. Statistical
; ****p < 0.0001 (n = 4).
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Figure 3. Ligand Binding Blocks HSV-1-Mediated, but Not HCMV-Mediated, Inhibition of Endogenous MR1 Surface Expression
(A and B) HFFs were mock or HSV-1 infected in parallel. Cells were either treated with Ac-6-FP (5 mM) for (A) 24 h prior to infection (pre) or (B) at 14 h p.i. (post)
before staining for surface MR1, MHC I at 18 h p.i., and analysis by flow cytometry. Fold change relative to mock infected cells is graphed. Statistical significance
was calculated by paired Student’s t test; **p < 0.005; ***p < 0.0005; ****p < 0.0001 (n = 3).
(C and D) HFFs were mock or HCMV infected in parallel. Cells were either treated with Ac-6-FP (5 mM) for (C) 24 h prior to infection (pre) or (D) at 8 h p.i. (post)
before staining for surface MR1, MHC I at 24 h p.i., and analysis by flow cytometry. Fold change relative to mock infected cells is graphed. Statistical significance
was calculated by paired Student’s t test; **p < 0.005; ***p < 0.0005 (n = 3).
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(0 h p.i.) before assaying MR1 levels by western blotting.
Although treatment with MG132 led to a reduction in total MR1
levels in mock infected cells, proteasomal inhibition completely
blocked the degradation of the remaining MR1 molecules in
HSV-1-infected cells, independent of presence/timing of ligand
addition. Levels of the viral protein ICP0 were higher in
MG132-treated cells, consistent with ICP0 being a known target
for proteasomal degradation (Nagel et al., 2011).
Proteasomal inhibition prior to infection is known to inhibit
HSV-1 infection (Delboy et al., 2008). Therefore, we confirmed
that treatment with MG132 at 0 h p.i. did not inhibit expression
of the HSV-1 late glycoprotein gD (Figure S7), demonstrating
that the recovery of MR1 levels post-MG132 treatment in HSV-
1 infection was not primarily due to inhibition of viral gene
expression. Treatment of mock or HSV-1-infected ARPE-19
MR1-GFP cells with either of the proteasomal inhibitors
MG132 or PS-341 could recover MR1-GFP fluorescence (a
measure of MR1 fusion protein levels) to that of mock infected
cells. This mirrored the immunoblot analysis (Figure 5B),
although MR1 surface expression in HSV-1-infected cells was
not fully recovered by either inhibitor (Figure 5C). This indicates
that MR1 is still retained within the infected cell, even when a
major cellular degradation pathway targeting this protein in
HSV-1 infection is inhibited, as has been previously described
for other MHC-like molecules regulated by herpesvirus infection
(Fielding et al., 2014).
Treatment with both MG132 and PS-341 led to a reduction in
cellular MR1 levels in mock infected cells (Figures 5A–5C)
compared to control-treated cells, suggesting that the protea-
some plays an important role in regulation of the homeostatic
levels of MR1 in this system. However, whether this is a direct ef-
fect on MR1 protein stability or other cellular components that
regulate MR1 remains to be elucidated.
HSV-1 Us3 Expression Modulates Surface MR1
Expression
To determine the role of de novo viral gene expression in regu-
lating MR1, the ability of UV-irradiated HSV-1 (UV-HSV-1) to
inhibit MR1 surface expression was assayed. ARPE-19 MR1
cells were mock, HSV-1, and UV-HSV-1 infected, with Ac-6-FP
added at 14 h p.i. before staining for MR1 at 18 h p.i. Although
UV-HSV-1 modestly reduced the surface levels of MR1, viable
HSV-1 was far more potent at targeting MR1, suggesting that
MR1 targeting is primarily dependent on de novo viral gene
expression (Figure 6A). Indeed, the substantial loss of MR1 pro-
tein seen at 6 h p.i. with viable virus was not apparent with UV-
HSV-1 (Figure 6B).Figure 4. HSV-1 Infection Inhibits Ligand and Bacterially Induced MAIT
(A) Representative histograms of CD69 expression on Jurkat MAIT (JM) cells incu
OP-RU (10 mM) or E. coli (200 colony-forming units [CFUs]/cell) as indicated.
(B and C) The fold change in CD69median fluorescence intensity (MFI) compared
4.
(D) Mock or HSV-1-fixed infected fibroblasts in co-culture with JM cells were
expression. The fold change in CD69 MFI compared to mock cells is graphed (n
(E) Representative histograms of CD69 expression of JM cells incubated with fi
E. coli (200 CFUs/cell) as indicated.
(F) The fold change in CD69 MFI compared to mock untreated ARPE-19 MR1 co-
by two-way ANOVA; ***p < 0.0005; ****p < 0.0001.The ICP0 protein of HSV-1 is known to direct a number of
cellular proteins key to viral control for proteasomal degradation
(Lanfranca et al., 2014) although the virion host shutoff (vhs) pro-
tein is a viral encoded RNase capable of degrading host cell
mRNAs to facilitate viral replication (Kwong and Frenkel, 1987).
Therefore, we determined whether these proteins could
contribute to HSV-1-mediated MR1 regulation using specific
viral mutant viruses (Everett et al., 2004; Fenwick and Everett,
1990). We first established that the parental strain of HSV-1
used for the mutants, strain 17, was as effective as the F strain
of HSV-1, used in all our previous analyses. Indeed, infection
with either the ICP0 and vhs mutants based on the 17 strain
both resulted in a loss of MR1 protein levels and surface expres-
sion at 18 h p.i. (Figure 6C). Thus, at late time points, neither ICP0
nor vhs are responsible for control of MR1.
We then expanded the study to a third HSV-1 gene. Us3 en-
codes a serine threonine kinase that is conserved among alpha-
herpesviruses (McGeoch and Davison, 1986). Us3 has profound
impacts on the infected cell while simultaneously promoting the
viral replicative cycle (Kato and Kawaguchi, 2018). In particular,
the Us3 protein has been shown to have viral immune modula-
tion activities, including inhibition of CD1d and MHC I antigen
presentation, resulting in reduced activation of NKT cells and
CD8+ T cells, respectively (Imai et al., 2013; Rao et al., 2011;
Xiong et al., 2015; Yuan et al., 2006). Thus, the viral protein
was expressed via transfection or lentiviral transduction of an
expression cassette consisting of Us3 with a downstream T2A
ribosome skipping motif and GFP. This enabled the flow-cytom-
etry-based selection of cells expressing Us3. Indeed, GFP-pos-
itive, Us3-expressing transfected/transduced cells showed that
surface MR1 was profoundly reduced compared to the untrans-
fected GFP-negative cells (Figure 7A). 293T cells transfected
with Us3-expressing plasmid and treated with Ac-6-FP ligand
6 h prior to harvesting demonstrated a significant loss of surface
MR1 compared to GFP-negative cells. Similarly, transduction
of 293T cells with Us3-expressing lentivirus, with or without
ligand, also resulted in loss of surface MR1 (Figure S8), although
transduced HFFs demonstrated a more modest but still signifi-
cant downregulation of MR1 (Figure 7B).
We then examined an Us3 deletion mutant HSV-1 to test
whether Us3 expression was essential to the modulation of
endogenous and overexpressed surface MR1 in the context of
productive infection. At 18 h p.i., ARPE-19 MR1 cells infected
with the Us3 mutant virus demonstrated a partial rescue of sur-
face MR1 compared to wild-type parental virus, both in the
absence of and following p.i. treatment with ligand (Figure 7C).
HFFs infected with the Us3 mutant also demonstrated aTCR-Driven Activation
bated with fixed mock or HSV-1-infected HFFs left untreated or treated with 5-
to mock cells incubated with JM cells for (B) 5-OP-RU, n = 6, and (C) E. coli, n =
incubated with 5-OP-RU (10 mM) overnight before staining for surface CD69
= 6).
xed mock or HSV-1-infected ARPE-19 MR1 treated with 5-OP-RU (10 mM) or
cultured with JM cells is graphed (n = 4). Statistical significance was calculated
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Figure 5. HSV-1 Targets the MR1 Protein for
Proteasomal Degradation
(A and B) ARPE-19 MR1 (A) or ARPE-19 MR1-GFP
(B) were mock or HSV-1 infected in parallel and
treated with MG132 (5 mM) immediately post-viral
adsorption as indicated. Cells were either left un-
treated or treated with Ac-6-FP (5 mM) for 24 h prior
to infection (pre) or at 14 h p.i. (post) before har-
vesting at 18 h p.i. and immunoblotting for MR1,
GFP, GAPDH, or ICP0.
(C) Mock or HSV-1-infected ARPE-19 MR1-GFPs
were treated with MG132 (5 mM) or PS-341 (100 nM)
immediately post-viral adsorption before addition of
Ac-6-FP at 14 h p.i. and staining for surface MR1 at
18 h p.i. Data are representative of 2 independent
experiments.significant rescue of surfaceMR1 compared to parental virus (Fig-
ure 7D). As expected, pre-treatment of either ARPE-19 MR1 cells
or HFFs with ligand prior to infection resulted in MR1 that was
resistant to targeting by parental HSV-1, and this remained the
case during infection with the Us3 mutant virus (Figures 7C and
7D). To examine whether Us3 is implicated in the loss of the total
MR1 pool by HSV-1, parental or mutant-virus-infected ARPE-19
MR1 cells were harvested at 2, 4, 6, and 18 h p.i. and analyzed
by immunoblot (Figure 7E), with similar patterns of viral gene
expression confirmed using HSV-1 gD expression. Both the2956 Cell Reports 30, 2948–2962, March 3, 2020wild-type and Us3 mutant demonstrated
comparable loss of cellular MR1 across
the time course of infection. Collectively,
these data suggest that Us3 is responsible
in part for loss of surface MR1, but other,
as yet unidentified viral product or products
are responsible for mediating the loss of to-
tal cellular MR1.
DISCUSSION
To date, there has been no infectious agent
identified to inhibit MR1 surface expression
to modulate immune recognition. Our
study provides evidence that multiple
herpesvirus infections can inhibit MR1 sur-
face expression, whereas adenovirus
infection could not. This indicates that the
ability of virus infection to control MR1 sur-
face expression is preserved across multi-
ple herpesviruses, suggesting evolutionary
conservation. The failure of adenovirus to
mediate this strongly indicates that MR1
regulation is not a global response to viral
infection but that it is rather a virus-driven
set of specific strategies that herpesvi-
ruses have evolved.
Focusing on regulation of MR1 by HSV-1
infection, it is clear that such control was
exquisitely sensitive to the timing of ligand
addition. Pre-treatment of cells with MR1ligand induced the protein to mature and become resistant to
viral-dependent targeting in both endogenous and overex-
pressed MR1. It is known that ligand binding to MR1 acts as a
driver to initiate the trafficking of molecules to the cell surface,
where it can be recognized by MAIT cells. The inability of HSV-
1 infection to efficiently target ligand-bound MR1 suggests that
such Ag binding could induce a change in the structure/glycosyl-
ation of MR1 that allows it to escape viral-mediated regulation.
Alternatively, mature MR1 traffics to a cellular compartment
not accessible to a HSV-1-encoded immunoevasin(s). It also
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Figure 6. HSV-1 Gene Expression Is Required
to Efficiently Inhibit MR1 Expression
(A) ARPE-19 MR1 were mock, HSV-1, or UV-HSV-1
infected. Cells were treated with Ac-6-FP (5 mM) at
14 h p.i. before staining for surface MR1 at 18 h p.i.
and analysis by flow cytometry. Fold change relative
to mock infected cells is graphed. Statistical signif-
icance was calculated by paired Student’s t test;
**p < 0.005; ***p < 0.0005; ****p < 0.0001 (n = 3).
(B) Cell lysates at 6 h p.i. from mock, HSV-1-, or UV-
HSV-1-infected ARPE-19 MR1 were immunoblotted
for MR1, GFP, or GAPDH.
(C) ARPE-19 MR1 were infected with the indicated
viruses and treated with Ac-6-FP at 14 h p.i. before
staining for surface MR1 18 h p.i. or immunoblotting
for MR1, GFP, or GAPDH.supports the hypothesis that HSV-1 can only targetMR1 in a pre-
Golgi compartment and not surface-plasma-membrane-associ-
ated MR1. Interestingly, HCMV infection could efficiently target
MR1 either pre- or post-treatment with ligand, suggesting that
these related viruses may have evolved additional or different
mechanisms to target MR1. This reflects the myriad of alterna-
tive mechanisms used by individual herpesviruses to control
expression of MHC and MHC-like molecules (Schmiedel and
Mandelboim, 2017; Schuren et al., 2016). This observation of
apparent differential regulation of MR1 expression by individual
viruses also suggests that herpesviruses may have evolved spe-
cific mechanisms to target MR1 under selective pressure from
the MR1:MAIT cell axis in an analogous manner to control ex-
erted by classical MHC-restricted responses.
Using UV-irradiated HSV-1, it was determined that the regula-
tion of MR1was largely dependent on de novo viral gene expres-
sion. However, neither of the viral proteins vhs nor ICP0 was
responsible for this phenotype observed. Subsequent analysis
identified that expression of the HSV-1 Us3 gene product in
isolationwas sufficient to downregulate cell surfaceMR1. Impor-
tantly, infection of cells with a HSV-1 Us3 deletion virus demon-
strated a partial rescue of cell surface, but not cellular, MR1.
These results identify Us3 as a viral mediator of MR1 regulation
independent of the capacity of HSV-1 to target MR1 for degrada-
tion. This is consistent with our observations that recovery of
MR1 protein levels by proteasomal inhibition during HSV-1 infec-
tion does not fully restoreMR1 cell surface expression. Together,
this implicates other, as yet unidentified, viral gene product(s) in
this phenotype, which is responsible for mediating the loss ofCell Rcellular MR1 protein levels detected at
early times post-HSV-1 infection.
It is perhaps unsurprising that HSV-1 can
apparently encodemultiplemechanisms to
regulate MR1 expression, given the varied
strategies herpesvirus family members
use to target the same antigen presenta-
tion molecule, e.g., MHC-I or CD1d (van
de Weijer et al., 2015). It should also be
noted that the major viral gene product
(ICP47) identified to regulate MHC-I-
dependent antigen presentation in HSV-1infection targets the transporter associated with antigen
processing (TAP) (Fr€uh et al., 1995). However, MR1 processing
is TAP independent (Huang et al., 2008; Treiner et al., 2003),
suggesting that herpesviruses have evolved independent mech-
anisms to target these divergent antigen presentation pathways.
This is supported by our observation that, although MR1 cell
surface expression during HSV-1 infection is differentially regu-
lated dependent on the timing of ligand addition, MHC I surface
expression is regulated similarly under both experimental condi-
tions (Figures 2 and 3).
It is becoming increasingly appreciated that interactions be-
tween viral, bacterial, fungal, and parasite infections can play
key roles in regulating host immunity, as well as in controlling
pathogen replication and pathogenicity (Pfeiffer and Virgin,
2016). Infection with HSV-1 predominantly manifests as lesions
in the skin, where the resident microbiome contains a vast array
of commensal and pathogenic microbiota capable of furnishing
MAIT cell antigens (Byrd et al., 2018). Thus, exposure to such
potentially activating antigens is likely a common feature of
HSV-1 infection. Indeed, HSV-1 infection has been demon-
strated to promote both bacterial and fungal infections with
intact riboflavin biosynthetic pathways (Plotkin et al., 2016;
Wang et al., 2012). In addition, the a-toxin of Staphylococcus
aureus can also directly promote HSV-1 infection (Bin et al.,
2012), underlining the potential for significant crosstalk be-
tween such microbes in the skin where MAIT cells are de-
tected. Thus, herpesvirus-encoded MR1 control may inhibit
MR1-restricted responses where Vit B Ag is provided by other
infections.eports 30, 2948–2962, March 3, 2020 2957
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HSV-1 infection could inhibit MR1-restrictedMAIT TCR-depen-
dent activation driven either by synthetic ligand or bacteria. Spe-
cifically, although HFFs and ARPE-19 cells exposed to 5-OP-RU
or E. coli were able to efficiently drive MR1-restricted MAIT TCR-
dependent activation, similarly treatedHSV-1-infected cells could
not, consistent with the potent inhibition of surface MR1 expres-
sion observed during infection. This provides evidence of path-
ogen control of MR1-restricted immune responses.
Initial reports indicated that viral infection (including HSV-1)
was not capable of directly activating MAIT cells derived from
a transgenic mouse model (Le Bourhis et al., 2010), but more
recent studies in humans have demonstrated both in vivo and
in vitro that MAIT cells can be activated by viral infections,
including influenza, dengue, hepatitis C, and Zika virus (Loh
et al., 2016; Paquin-Proulx et al., 2018; van Wilgenburg et al.,
2016). Activation was not inhibited by MR1-neutralizing Ab and
was primarily dependent on the cytokines IL-12 and IL-18 (Loh
et al., 2016; van Wilgenburg et al., 2016). In addition, MAIT cells
were activated by influenza infection in a murine model with
MR1-deficient mice being significantly more susceptible to se-
vere influenza infection (van Wilgenburg et al., 2018). Several
recent reports have also identified dysregulation of MAIT cell
number and function in patients as a characteristic of chronic
viral infection, in particular, HIV and HCV infection. In HIV/AIDS
patients, at both early times p.i. and in chronic viral infection
up to 8 years p.i., circulating MAIT cell frequency is reduced
with some, but not all, studies detecting a defect in MAIT cell
function (Cosgrove et al., 2013; Fernandez et al., 2015; Leean-
syah et al., 2013, 2015). MAIT cells are the lymphocyte subset
most profoundly affected in chronic HCV infection, with average
MAIT cell number reduced by more than 80% compared to
healthy individuals (Barathan et al., 2016; Hengst et al., 2016).
In addition, MR1-dependent MAIT cell function was reduced
fromHCV-infected individuals (Hengst et al., 2016). Furthermore,
a decrease in MAIT cell number was associated with fatal infec-
tions from influenza H7N9 infection (Loh et al., 2016). The factors
driving alterations in circulating MAIT cell numbers and function
during viral infection, including the potential role of MR1, remain
to be fully elucidated.
Although a potential role for MAIT cells during herpesvirus in-
fections in vivo remains to be explored, it is intriguing that a range
of primary immunodeficiencies, particularly associated with se-
vere herpesvirus infections, including HSV-1 and HCMV (Latour
and Winter, 2018), are characterized by profound reductions in
circulating MAIT cell number, including mutations in cytidine
triphosphate synthase 1 (Martin et al., 2014), RAS guanyl
releasing protein 1 (Winter et al., 2018), CD70 (Izawa et al.,Figure 7. HSV-1 Us3 Expression Modulates Surface MR1
(A) 293T cells transfected with plasmid expressing HSV-1 Us3 (pSY10-Us3).
(B) HFFs transduced with lentivirus expressing HSV-1 Us3 were treated with Ac-6
with gating on GFP expression to identify Us3-expressing GFP+ cells. Fold chan
paired Student’s t test (n = 3).
(C and D) ARPE-19 MR1 (C) or HFFs (D) were mock, HSV-1 KOS, or DUs3 infected
or at 14 h p.i. (post) before staining for surface MR1 at 18 h p.i. and analysis by flo
significance was calculated by ANOVA; *p < 0.05; **p < 0.005; ***p < 0.0005; ****
(E) Cell lysates frommock, HSV-1 KOS-, orDUs3-infected ARPE-19 MR1 cells ha
Data are representative of 2 independent experiments.2017), X-linked inhibitor of apoptosis (Ge´rart et al., 2013), and
coronin-1A (Moshous et al., 2013). Circulating MAIT cell number
is also reduced in HCMV seropositive compared to seronegative
individuals (Patin et al., 2018), suggesting that herpesvirus infec-
tions may have the capacity to regulate this specific immune
subset. Primary herpesvirus infection is followed by lifelong
persistence in a latent state, from which these viruses can reac-
tivate to potentially cause disease. Therefore, it would also be
intriguing to investigate whether latently infected cells also retain
the capacity to control MR1 surface expression to facilitate
evasion of MR1-restricted immune responses throughout the
lifespan of the host.
To date, nomammalian and/or virally encodedMR1 ligand has
been identified, and studies in the context of viral infection sug-
gest thatMAIT cell activity is primarily controlled in anMR1-inde-
pendent fashion. Therefore, it is not obvious that viruses should
encode mechanisms to regulate MR1. However, there are re-
ports indicating that such host-encoded antigens may exist
(Lepore et al., 2017; Ling et al., 2016), particularly in the context
of MAIT cell development prior to microbial colonization (Koay
et al., 2018). In our study, we could not detect activation driven
through a MAIT TCR by virus-infected cells alone, consistent
with previous reports. However, a more detailed analysis of
the potential for viral infection to drive MR1-restricted T cell
responses is warranted, given our data indicating that multiple
viruses from different species have evolved mechanisms to
regulate MR1 surface expression.STAR+METHODS
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construct (Figure S9). This was then introduced into HSV-1 strain KOS strain by homologous recombination before mutants were
identified by fluorescence and purified by plaque picking. The mutant was confirmed by DNA sequencing and loss of protein kinase
function. Human adenovirus type 5 (Ad) and DE3/19k mutants derived from BAC clones (pAL908 and pAL918 respectively) were
grown and titrated in A549 cells as described previously (McSharry et al., 2008). Murine cytomegalovirus Smith strain (Rawlinson
et al., 1996) provided by Prof William Rawlinson (University of New South Wales) was grown and titrated in NIH 3T3 fibroblasts. Hu-
man cytomegalovirus (Merlin strain) generated from the BAC clone pAL1111 provided by Dr Richard Stanton (Cardiff University) was
grown and titrated in HFFs (Stanton et al., 2010).
Plasmid expression constructs
Primers (Forward: 50 GTCTACACTAGTATGGCCTGTCGTAAGTTTTGTCG 30; reverse: 50 GTCTACAGATCTTTTCTGTTGAAA
CAGCGGCAAAC 30; Us3 sequence underlined, restriction sites in bold) were used to amplify the HSV-1 Strain F Us3 sequence
excluding the stop codon. PCR products were purified (GFX PCR DNA and Gel Band Purification Kit) and digested (SpeI-HF and
BglII, NEB). The plasmid backbone (pCDH_EF1-MCS-T2A-copGFP vector, Systems Bioscience, USA) was digested (XbaI
and BamHI-HF, NEB), purified and ligated to the Us3 fragment (T4 DNA ligase NEB) to create the pSY10-Us3 plasmid. This
was transformed into NEB 5-alpha E. coli, selected on Luria-Bertani agar with ampicillin (50 mg/ml) and purified (Macherey-Nagal
NucleoSpin). Cells were transfected with pSY10-Us3 using Fugene HD (Promega), and replication-deficient pSY10-Us3 lentivirusCell Reports 30, 2948–2962.e1–e4, March 3, 2020 e3
were synthesized in 293T cells co-transfected with lentiviral packaging plasmids as previously described (Ashley et al., 2017). Cells
were transduced using in the presence of 5 mg/mL Polybrene (Sigma-Aldrich).
METHOD DETAILS
Virus Infections
Cells were infected with HSV-1 at an MOI of either 5 (F and KOS strains) or 3 (17 strain) by incubating for 1 hour with gentle rocking.
HCMV andMCMV infections were performed at anMOI of 10. Ad infections were performed at anMOI 30 (HFF) or MOI 10 (293 cells).
All cells were incubated at 37C in 5% CO2.
Flow cytometry analysis
For flow cytometry staining of MR1 in HFFs the mAb 26.5 conjugated to Biotin in combination with Streptavidin conjugated to PE or
APC (eBioscience) was utilized. In MR1 overexpressing cells 26.5 directly conjugated to PE (Biolegend) was used. Surface MHC I
expressionwasdetected by anti-HLA-A,B,C-PE (Miltenyi Biotec) or anti-HLA-A,B,C-APC (BDBiosciences). HSV-1 gD surface expres-
sion was detected using anti-gD-FITC (Virostat). Live cells were identified using Zombie NIR Fixable Viability Kit (Biolegend). Flow cy-
tometry was performed using a LSR Fortessa X-20 (BD Biosciences), with data analyzed using FlowJo software (Treestar Inc.).
MR1 ligands
The MR1 ligands Ac-6-FP (Schircks Laboratories) and 5-OP-RU (synthetic 5-A-RU plus methylglyoxal (Sigma-Aldrich) at equimolar
concentrations) were added to the culture medium at the concentrations indicated.
Bacteria
E. coli (DH5a) Life technologies were grown o/n to saturation in Luria-Bertani broth. The following morning the bacteria were pelleted
and washed in PBS before fixation in 1% paraformaldehyde for 3 minutes with vortexing for the first 60 s and last 30 s of the fixation
(Dias et al., 2017). The cells were washed 4 times with PBS before being added to cells at 200 colony forming units per cell as deter-
mined by colony counts.
Jurkat MAIT cell activation assays
5 3 104 (HFFs) or 1 3 105 (ARPE-19 MR1) mock or HSV-1 infected cells in 24-well plates at 14 h p.i. were treated with 5-OP-RU
(10 mM) or E. coli for 4 hours before being washed from the system at 18 h p.i. Cells were then fixed with 1% paraformaldehyde
and 2% glucose in PBS for 20 min at 4C, before washing 3 times with complete media. Jurkat MAIT cells (33 105) were then added
in folate free RPMI1640 and allowed to incubate o/n before staining for CD69 (BD Biosciences) expression as a measure of Jurkat
MAIT activation. 5-OP-RU (10 mM) was added to HFF/Jurkat MAIT co-cultures or to Jurkat MAIT cells alone and allowed to incubate
o/n as indicated.
Immunoblotting
Cells were harvested in cell lysis buffer (50 mM NaCl, 50 mM TRIS pH8, 1% IGEPAL, 1% Triton X-100) supplemented with protease
inhibitor cocktail (Sigma) and allowed to incubate on ice for 20 mins. Lysates were then centrifuged (16,000 x g for 20 min at 4C) and
the supernatant collected. Lysates were mock or Endo H (NEB) digested according to the manufacturer’s instructions for 90 mins at
37C as required. Lysates were denatured by heating at 95C for 5 mins in reducing sample buffer (Bio-Rad) and resolved by SDS-
PAGE on precast polyacrylamide gels (Biorad) before immunoblotting onto PVDF membranes. Membranes were probed with the
designated primary antibodies in 3% BSA in PBST, followed by incubation with an appropriate horseradish peroxidase (HRP)-con-
jugated secondary antibody (all Santa Cruz Biotechnology). The following primary antibodies were utilized: anti-MR1 CT (McWilliam
et al., 2016), anti-MR1 and anti-HLA-A, B, C (Abcam), anti-GFP, anti-GAPDH, anti-gD, and anti-ICP0 (all Santa Cruz Biotechnology).
Proteasomal Inhibition
After the 1 h of viral adsorption, cells were treated with either 5 mM MG132 (Sigma-Aldrich), 100 nM PS-341 (Selleck Chemicals) or
DMSO control (Sigma) to inhibit proteasomal activity.
QUANTIFICATION AND STATISTICAL ANALYSIS
Paired Student’s t tests or ANOVA analysis were performed as indicated using GraphPad Prism software. Data are presented as dot
plots with the mean.
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